Maplight Therapeutics (NASDAQ:MPLT) Director Timothy John Garnett Buys 14,124 Shares

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Timothy John Garnett bought 14,124 shares of the stock in a transaction on Tuesday, February 10th. The stock was purchased at an average cost of $17.89 per share, with a total value of $252,678.36. Following the completion of the purchase, the director directly owned 14,124 shares in the company, valued at $252,678.36. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Maplight Therapeutics Trading Down 3.1%

Shares of Maplight Therapeutics stock opened at $17.22 on Friday. Maplight Therapeutics, Inc. has a fifty-two week low of $12.24 and a fifty-two week high of $21.55. The business’s fifty day simple moving average is $18.17. The stock has a market cap of $781.27 million and a price-to-earnings ratio of -0.46.

Maplight Therapeutics (NASDAQ:MPLT) last released its earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Wall Street Analyst Weigh In

MPLT has been the topic of a number of research analyst reports. Zacks Research upgraded shares of Maplight Therapeutics to a “hold” rating in a report on Monday, November 24th. Morgan Stanley assumed coverage on Maplight Therapeutics in a research report on Friday, November 21st. They issued an “overweight” rating and a $34.00 target price on the stock. Wall Street Zen raised Maplight Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Leerink Partners started coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set an “outperform” rating and a $30.00 price target for the company. Finally, Weiss Ratings initiated coverage on Maplight Therapeutics in a research note on Thursday, January 22nd. They issued a “sell (e)” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.00.

Institutional Trading of Maplight Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Strs Ohio purchased a new position in Maplight Therapeutics in the fourth quarter valued at about $53,000. New York State Common Retirement Fund acquired a new stake in shares of Maplight Therapeutics in the fourth quarter valued at about $93,000. MetLife Investment Management LLC purchased a new stake in shares of Maplight Therapeutics during the 4th quarter valued at about $172,000. Deutsche Bank AG purchased a new stake in shares of Maplight Therapeutics during the 4th quarter valued at about $210,000. Finally, Nuveen LLC acquired a new position in Maplight Therapeutics during the 4th quarter worth approximately $355,000.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.